Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements By Ogkologos - June 11, 2026 179 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FIGHT-302 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST... March 10, 2026 Nivolumab Plus Low-Dose Ipilimumab Demonstrates Clinical Benefit in First-Line Treatment for... October 20, 2021 Grandma Saves Her Money To Put Up A Billboard For Everyone... June 14, 2019 FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma April 27, 2022 Load more HOT NEWS Medicare Open Enrollment is Here! GreaterGood Partners with Organization of Hope to Deliver Toys and Necessities... Substantial Clinical Activity of Teclistamab in Patients with Heavily Pretreated Relapsed... Judge Rules That 3-Year-Old Child With Leukemia Must Get Chemo Against...
